Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 10/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | BAD | Q92934 | 1/20 | 0.41 |
| ▸ | QDPR | P09417 | 1/20 | 0.37 |
| ▸ | USP7 | Q93009 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2049785 | 0.84 | BCL2L1 (0.42) | HTR2CBCL2L1BADHTR2B | |
| SCHEMBL5937367 | 0.77 | HTR2C (0.45) | HTR2CHTR2B | |
| SCHEMBL5899937 | 0.74 | QDPR (0.45) | QDPR | |
| SCHEMBL6709392 | 0.73 | FEN1 (0.43) | HTR2C | |
| SCHEMBL6794310 | 0.71 | SLC6A2 (0.38) | HTR2C | |
| SCHEMBL24947638 | 0.70 | HTR2C (0.53) | HTR2CQDPRSLC18A3SIGMAR1ADRB2 | |
| SCHEMBL5899890 | 0.70 | SLC6A4 (0.45) | SIGMAR1 | |
| SCHEMBL5899888 | 0.70 | SLC6A2 (0.62) | — | |
| SCHEMBL24120085 | 0.69 | HTR2C (0.51) | HTR2CSLC18A3SIGMAR1ADRB2 | |
| Hydrochloric Acid SCHEMBL28731235 | 0.69 | HTR2C (0.54) | HTR2CQDPRSLC18A3SIGMAR1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | BOUILLOT ANNE (FR) | 2004-07-29 | — | — | US | disclosed |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-22 | — | — | US | disclosed |
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| EP-1351935-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| EP-1351937-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2003-10-15 | — | — | EP | disclosed |
| WO-2002055495-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
| WO-2002055497-A1 | ARYL PIPERIDINE DERIVATIVES AS INDUCERS OF LDL-RECEPTOR EXPRESSION | GLAXO GROUP LIMITED (GB) | 2002-07-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147557-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | HTR2C 233/4885BCL2L1 1092/4885BAD 1263/4885 |
| US-20040072865-A1 | Aryl piperidine derivatives as inducers of ldl-receptor expression | NR1H2, NR1H3, NR1H4 | HTR2C 217/4885BCL2L1 1110/4885BAD 1053/4885 |
| US-20040077654-A1 | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression | LDLR, NR1H2, NCOR1 | HTR2C 1120/4885BCL2L1 1469/4885BAD 601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.